Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
A phase 1/2 trial of EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Ellipses Pharma, now recruiting.
Overview
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT05573126 by Ellipses Pharma, with 95 participants planned, started 2023-01-11 and due to reach its primary completion in 2028-02. Interventions recorded: EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane.
Similar pages
not linked directly; found by shared links- TrialStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Shares Exemestane, Everolimus, Fulvestrant and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Shares Exemestane, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Exemestane, Abemaciclib, Fulvestrant and the tag pipeline.
- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares Exemestane, Fulvestrant and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Abemaciclib, Fulvestrant and the tag pipeline.
- TrialA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Shares Exemestane, Elacestrant and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Abemaciclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.